PneumoADIP: An Example of Translational Research to Accelerate Pneumococcal Vaccination in Developing Countries

By Levine, Orin S.; Cherian, Thomas et al. | Journal of Health Population and Nutrition, September 2004 | Go to article overview

PneumoADIP: An Example of Translational Research to Accelerate Pneumococcal Vaccination in Developing Countries


Levine, Orin S., Cherian, Thomas, Shah, Raj, Batson, Amie, Journal of Health Population and Nutrition


INTRODUCTION

Few pathogens rival Streptococcus pneumoniae as a cause of childhood illness and death. According to the estimates of the World Health Organization, pneumococcal infections kill more than one million children aged less than five years every year--more than any other vaccine-preventable infection, including measles (1). Unlike HIV and malaria, effective vaccines for the prevention of pneumococcal infections are currently available (2).

Pneumococcal conjugate vaccines, like Haemophilus influenzae type b (Hib) conjugates, are safe and highly efficacious for preventing serious infections, such as sepsis, pneumonia, and meningitis (3-5). The vaccines also prevent ear infections and pharyngeal colonization and reduce transmission from vaccinated infants to unvaccinated contacts (6-9). A vaccine containing seven important pneumococcal serotypes has been routinely used for vaccinating infants in the United States since 2000. Its routine use has led to herd immunity, i.e. a decreased incidence of disease among unimmunized persons (10,11). Avaccine containing two additional serotypes of importance in developing countries (in total, nine serotypes) was recently shown to be highly efficacious for preventing pneumonia and invasive infections in African children, including those infected with HIV (5). Based on these results, pneumococcal conjugate vaccines appear to be promising tools for improving child health globally. Further research is still needed to assess their effectiveness in other geographic regions, such as Asia, where differences in the local serotype distribution may modify the impact the existing 9- or 11-valent vaccines can have, and more local data will be needed to support national decisions to introduce the vaccines.

Given its enormous global burden of disease, it would seem obvious that, once developed, highly-effective vaccines would be demanded by, and supplied to, developing countries. Unfortunately, the experience with Hib conjugate and hepatitis B vaccines shows that the uptake of these life-saving vaccines has been the slowest in the developing world where, ironically, they are needed the most (12-14).

To accelerate the availability of pneumococcal conjugate vaccines in developing countries, the Global Alliance for Vaccines and Immunizations (GAVI) has launched a project management team called the Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP). Based at Johns Hopkins Bloomberg School of Public Health, this team was awarded US$ 30 million to coordinate a targeted, multi-partner workplan to help GAVI achieve its objectives for pneumococcal vaccination.

LEARNING FROM THE PAST: LESSONS FROM HIB AND HEPATITIS B VACCINES

Hepatitis B and Hib vaccines are safe and effective, can be administered through routine immunization systems, and address important global health problems. These vaccines are routinely used for vaccinating infants in nearly all industrialized countries. However, even as much as 14 years after the introduction of Hib vaccines in industrialized countries, less than 10% of infants in the 75 poorest countries of the world were routinely receiving these vaccines (Fig. 1).

Several factors contributed to the slow uptake of these vaccines. One of the most important factors was the lack of a coordinated effort to address both demand and supply issues before launching of the vaccines in developing countries. While the public sector often sponsored surveillance and research demonstrating the burden of disease or effectiveness of vaccine, there was no accompanying communication effort to assure that the data reached policy-makers. Further compounding the problems, efforts to assure financing for the procurement of vaccine--especially in early years when supplies are constrained and product prices tend to be higher as firms recoup development costs--were limited. Manufacturers of vaccines saw little or no evidence of market demand--i. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

PneumoADIP: An Example of Translational Research to Accelerate Pneumococcal Vaccination in Developing Countries
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.